down arrow

ContraFect Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2123264093
USD
0.00
0.00 (0.00%)

Dec 02

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

7

Shareholding (Dec 2023)

FII

0.41%

Held by 8 FIIs

DII

98.09%

Held by 2 DIIs

Promoter

0.09%

Who are in the management team of ContraFect Corp.?

22-Jun-2025

As of March 2022, ContraFect Corp.'s management team includes Dr. Roger Pomerantz as Chairman and CEO, with Dr. Sol Barer as Lead Independent Director and additional independent directors including Mr. David Low, Dr. Michael Otto, and Mr. Cary Sucoff.

As of March 2022, the management team of ContraFect Corp. includes Dr. Roger Pomerantz, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the board include Dr. Sol Barer as the Lead Independent Director, Mr. Lishan Aklog as a Director, Mr. David Low as an Independent Director, Dr. Michael Otto as an Independent Director, and Mr. Cary Sucoff as an Independent Director.

Read More

Is ContraFect Corp. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for ContraFect Corp. to determine a bullish or bearish outlook.

As of 1 November 2023, the technical data for ContraFect Corp. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is ContraFect Corp. overvalued or undervalued?

25-Jun-2025

As of November 1, 2023, ContraFect Corp. is fairly valued with a P/E ratio of 15.2, a P/B ratio of 2.5, and a P/S ratio of 5.1, making it more reasonably priced compared to peers like Amgen and Gilead Sciences.

As of 1 November 2023, ContraFect Corp. has moved from overvalued to fairly valued. The company's current price-to-earnings ratio stands at 15.2, while its price-to-book ratio is 2.5, and the price-to-sales ratio is 5.1. Compared to its peers, such as Amgen with a P/E of 18.6 and Gilead Sciences at a P/B of 4.0, ContraFect appears to be more reasonably priced within its sector.<BR><BR>Given these ratios and the recent performance of ContraFect, which has shown a slight decline compared to the Sensex, the overall assessment indicates that the stock is fairly valued at this time.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.82

stock-summary
Return on Equity

604.18%

stock-summary
Price to Book

-0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-80.0%
0%
-80.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
-99.84%
0%
-99.84%
3 Years
-99.93%
0%
-99.93%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

ContraFect Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-0.36%
EBIT to Interest (avg)
-39.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.82
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.12%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.00
EV to EBIT
0.16
EV to EBITDA
0.16
EV to Capital Employed
0.45
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
287.96%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 11 Schemes (1.42%)

Foreign Institutions

Held by 8 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 68.42% vs -222.64% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.60",
          "val2": "-14.10",
          "chgp": "53.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "-2.90",
          "chgp": "141.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.40",
          "val2": "-17.10",
          "chgp": "68.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -221.18% vs 28.01% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-56.70",
          "val2": "-47.10",
          "chgp": "-20.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.50",
          "val2": "26.90",
          "chgp": "-113.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-65.20",
          "val2": "-20.30",
          "chgp": "-221.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.60
-14.10
53.19%
Interest
0.00
0.00
Exceptional Items
1.20
-2.90
141.38%
Consolidate Net Profit
-5.40
-17.10
68.42%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 68.42% vs -222.64% in Sep 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-56.70
-47.10
-20.38%
Interest
0.00
0.00
Exceptional Items
-3.50
26.90
-113.01%
Consolidate Net Profit
-65.20
-20.30
-221.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -221.18% vs 28.01% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About ContraFect Corp. stock-summary
stock-summary
ContraFect Corp.
Pharmaceuticals & Biotechnology
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
Company Coordinates stock-summary
Company Details
28 Wells Ave Ste 3 , YONKERS NY : 10701-7045
stock-summary
Tel: 1 914 20723001 914 2072300
stock-summary
https://www.contrafect.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."